The document's conclusion cannot be provided because the document is not available or cannot be read.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
20 citations
,
September 2013 in “Anti-Cancer Drugs” PTH-CBD could help prevent and treat hair loss caused by chemotherapy in mice.
277 citations
,
July 2002 in “Molecular Endocrinology” Removing part of the vitamin D receptor stops vitamin D from working properly.
May 2024 in “Deleted Journal” Cancer treatments can cause hair loss, but it is often reversible and can be managed with scalp cooling and support.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
2 citations
,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
February 2026 in “International Journal of Clinical Dermatology” A multi-drug treatment can effectively clear extensive calcinosis in juvenile dermatomyositis.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” DNCB is more effective than betamethasone for hair regrowth but has more side effects.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
December 2023 in “European Journal of Pharmacology” C3G and Vitisin A may help prevent hair loss by blocking male hormones and stopping hair cell death.
June 2023 in “Current Issues in Molecular Biology” DN106212, an extract from a plant, is better at promoting hair growth than other tested substances by affecting hair growth factors and follicle development.
November 2025 in “Сибирский научный медицинский журнал” TS-13 speeds up hair regrowth after chemotherapy.
1 citations
,
June 2018 in “Dermatologic Surgery” 7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
June 2023 in “Journal of Clinical Oncology” CDK4/6 inhibitors may cause hair loss in breast cancer patients.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
21 citations
,
April 2008 in “Toxicologic Pathology” CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
February 2026 in “Clinical Drug Investigation” Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
August 2016 in “Journal of Dermatology” A chemical called 5-Bromo-2′-deoxyuridine caused rapid hair loss in mice by killing certain skin cells through a specific cell death pathway.
12 citations
,
August 2011 Prompt treatment of tinea capitis with oral antifungals leads to excellent recovery, but delayed care can cause permanent hair loss.
1 citations
,
September 2001 in “PubMed” Acitretin treats severe skin conditions but requires careful monitoring due to serious side effects.
November 2018 in “Annals of oncology” A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.
44 citations
,
April 2006 in “Expert opinion on drug safety” Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.